摘要
目的探究和分析枸橼酸铋钾治疗幽门螺杆菌(helicobacter pylori,Hp)阳性消化性溃疡的效果及对患者超敏C反应蛋白、白细胞介素-17等炎症因子水平的影响。方法目的选取仁怀市人民医院2023年12月—2024年3月收治的80例Hp阳性消化性溃疡患者作为研究对象,根据治疗方式不同,分为对照组和观察组,每组40例。对照组治疗方法为三联疗法,观察组治疗方法为三联疗法联合枸橼酸铋钾,对比两组患者治疗前后的炎症因子水平、不良反应发生率及治疗总有效率。结果治疗后,观察组患者炎症因子低于对照组,观察组患者不良反应发生率低于对照组,差异有统计学意义(P均<0.05)。观察组治疗总有效率为95.00%(38/40)高于对照组的80.00%(32/40),差异有统计学意义(χ^(2)=4.114,P<0.05)。结论枸橼酸铋钾治疗Hp阳性消化性溃疡的效果较好,能改善患者机体炎症因子水平,且不良反应少,值得临床应用。
Objective To explore and analyze the efficacy of bismuth potassium citrate in the treatment of Hp positive peptic ulcers and its impact on the levels of inflammatory factors such as hypersensitive C-reactive protein and interleukin-17 in patients.Methods Eighty patients with Hp positive peptic ulcers admitted to Renhuai People's Hospital from December 2023 to March 2024 were objectively selected as the study subjects.According to different treatment methods,they were divided into control group and observation group,with 40 cases in each group.The control group was treated with triple therapy,and the observation group was treated with triple therapy combined with bismuth sodium citrate.The levels of inflammatory factor,incidence of adverse reactions,and total effective rate of treatment were compared between the two groups before and after treatment.Results After treatment,the hypersensitive C-reactive protein and interleukin-17 were lower in observation group compared to the control group.The incidence of adverse reactions in the observation group was lower than that in the control group,the differences were statistically significant(all P<0.05).The total effective rate of treatment was 95.00%(38/40),which was higher than the control group's 80.00%(32/40),the difference was statistically significant(χ^(2)=4.114,P<0.05).Conclusion Potassium bismuth citrate has a good therapeutic effect on Hp positive peptic ulcers,improving the levels of inflammatory factors in patients with minimal toxic side effects.It is worthy of clinical application.
作者
魏坤
WEI Kun(Digestive Department,Renhuai People's Hospital,Renhuai 564500,Guizhou,China)
出处
《系统医学》
2024年第14期178-180,185,共4页
Systems Medicine
